Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Firefly Neuroscience (AIFF) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for Firefly Neuroscience (AIFF) over the last 15 years, with Q3 2025 value amounting to $269000.0.

  • Firefly Neuroscience's Current Deferred Revenue changed N/A to $269000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $269000.0, marking a year-over-year change of. This contributed to the annual value of $13000.0 for FY2024, which is N/A changed from last year.
  • Latest data reveals that Firefly Neuroscience reported Current Deferred Revenue of $269000.0 as of Q3 2025.
  • In the past 5 years, Firefly Neuroscience's Current Deferred Revenue registered a high of $455496.0 during Q1 2021, and its lowest value of $13000.0 during Q4 2024.
  • For the 5-year period, Firefly Neuroscience's Current Deferred Revenue averaged around $152026.1, with its median value being $127091.0 (2023).
  • The largest annual percentage gain for Firefly Neuroscience's Current Deferred Revenue in the last 5 years was 6820.94% (2021), contrasted with its biggest fall of 8026.84% (2021).
  • Over the past 5 years, Firefly Neuroscience's Current Deferred Revenue (Quarter) stood at $186835.0 in 2021, then fell by 2.18% to $182756.0 in 2022, then plummeted by 85.76% to $26026.0 in 2023, then plummeted by 50.05% to $13000.0 in 2024, then soared by 1969.23% to $269000.0 in 2025.
  • Its Current Deferred Revenue stands at $269000.0 for Q3 2025, versus $326000.0 for Q2 2025 and $13000.0 for Q4 2024.